Skip to main content
SpringerLink
Log in

Tramadol Extended-Release Tablets in Moderate to Moderately Severe Chronic Pain in Adults

Profile Report

  • Adis Profile Report
  • Published:
CNS Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Hair PI, Curran MP, Keam SJ. Tramadol extended-release tablets. Drugs 2006; 66(15): 2017–27

    Article  PubMed  CAS  Google Scholar 

  2. Davis MP. Tramadol extended-release tablets: a viewpoint. Drugs 2006; 66(15): 2028

    Article  Google Scholar 

  3. Sachs CJ. Tramadol extended-release tablets: a viewpoint. Drugs 2006; 66(15): 2028–9

    Article  Google Scholar 

  4. McCarberg BH. Tramadol extended-release tablets: a viewpoint. Drugs 2006; 66(15): 2029–30

    Article  Google Scholar 

  5. Best Practice Committee of the Health Care Association of New Jersey. Hamilton (NJ). Pain management guideline [online]. Available from URL: http://www.hcanj.org/docs/hcanjbp_painmgmt2.pdf [Accessed 2006 Oct 4]

  6. Wisconsin Medical Society Task Force on Pain Management. Guidelines for the assessment and management of chronic pain. Wis Med J 2004; 103(3): 15–42

    Google Scholar 

  7. ULTRAM® (Tramadol hydrochloride tablets). US prescribing information May 2004. Raritan (NJ): Ortho-McNeil Pharmaceutical Inc. [online]. Available from URL: http://www.onhomcneil.com [Accessed 2006 Oct 2]

  8. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43(13): 879–923

    Article  PubMed  CAS  Google Scholar 

  9. Keating GM. Tramadol sustained-release capsules. Drugs 2006; 66(2): 223–30

    Article  PubMed  CAS  Google Scholar 

  10. Mattia C, Coluzzi F. Once-daily tramadol in rheumatological pain. Expert Opin Pharmacother 2006; 7(13): 1811–23

    Article  PubMed  CAS  Google Scholar 

  11. ULTRAM® ER (tramadol HC1) extended-release tablets: an oral once-daily formulation of tramadol. Formulary 2006 Sep; 41 Suppl.: 1-17

  12. Biovail Corporation. Investor conference: June 28, 2005 [online]. Available from URL: http://www.biovail.com/local/ files/Commercial%20Operations.pdf [Accessed 2006 Sep 29]

  13. Modified release formulations of at least one form of tramadol. United States patent application: 20060099249. Kind code: A1. Inventors: Seth, Pawan, et al. May 11, 2006 [online]. Available from URL: http://www.uspto.gov [Accessed 2006 Oct 1]

  14. Biovail Corporation. Biovail Corp International 20-F for 12/31/ 05 [online]. Available from URL: http://www.secinfo.com/dVut2.v49s.htm [Accessed 2006 Sep 24]

  15. ULTRAM® ER (Tramadol HCl) extended-release tablets. US prescribing information January 2006. Raritan (NJ): Ortho-McNeil Inc. [online]. Available from URL: http://www.orthomcneil.com [Accessed 2006 Oct 2]

  16. Lai JC, Sista S, Eradiri O, et al. The pharmacokinetics of novel once daily tramadol hydrochloride extended release tablets in healthy subjects [abstract no. M1071]. AAPS PharmSci 2003; 5 Suppl. 1. Plus poster presented at the Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists; 2003 Oct 26–30; Salt Lake City (UT)

  17. Eradiri O, Sista S, Lai JC-K, et al. Bioavailability of extended-release and immediate-release formulations of tramadol HCl [abstract no. 126]. J Clin Pharmacol 2006; 46(9): 1091. Plus poster presented at the 35th Annual Meeting of the American College of Clinical Pharmacology; 2006 Sep 17–19; Cambridge (MA)

    Google Scholar 

  18. Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004; 28(1): 59–71

    Article  PubMed  CAS  Google Scholar 

  19. Gana TJ, Pascual MLG, Fleming RRB, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. 023 Study Group. Curr Med Res Opin 2006; 22(7): 1391–401

    Article  CAS  Google Scholar 

  20. Pedersen RS, Damkier P, Brosen K. Enantioselective pharma-cokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006; 62(7): 513–21

    Article  PubMed  CAS  Google Scholar 

  21. Ide S, Minami M, Ishihara K, et al. Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology 2006; 51(3): 651–8

    Article  PubMed  CAS  Google Scholar 

  22. Enggaard TP, Poulsen L, Arendt-Nielsen L, et al. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 2006; 102(1): 146–50

    Article  PubMed  CAS  Google Scholar 

  23. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med 2006; 260(1): 76–87

    Article  PubMed  CAS  Google Scholar 

  24. Barann M, Urban B, Stamer U, et al. Effects of tramadol and Odemethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol 2006; 531(1–3): 54–8

    Article  PubMed  CAS  Google Scholar 

  25. Cepeda MS, Camargo F, Zea C, et al. Tramadol for osteoarthritis. Cochrane Database Syst Rev 2006 Jul 19; 3: CD005522

    PubMed  Google Scholar 

  26. Cepeda MS, Africano JM, Polo R, et al. What decline in pain intensity is meaningful to patients with acute pain? Pain 2003; 105(1–2): 151–7

    Article  PubMed  Google Scholar 

  27. Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med 2001; 38(6): 633–8

    Article  PubMed  CAS  Google Scholar 

  28. Bianchi M, Broggini M, Balzarini P, et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin-6 in patients with knee osteoarthritis: comparison with paracetamol. Int Immunopharmacol 2003; 3(13–14): 1901–8

    Article  PubMed  CAS  Google Scholar 

  29. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43(9): 1905–15

    Article  Google Scholar 

  30. Hudson L, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib or non-steroidal anti-inflammatory drugs: population based study. BMJ 2005 Jun 11; 330(7504): 1370

    Article  PubMed  CAS  Google Scholar 

  31. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99(3): 132–40

    Article  PubMed  CAS  Google Scholar 

  32. National Pharmaceutical Council, Inc., Joint Commission on Accreditation of Healthcare Organizations. Pain: current understanding of assessment, management, and treatments. Reston (VA): National Pharmaceutical Council, Inc., 2001 [online]. Available from URL: http://www.npcnow.org/resources/PDFs/painmonograph.pdf [Accessed 2006 Sep 26]

  33. Weinstein SM, Laux LF, Thornby JI, et al. Physicians’ attitudes toward pain and the use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. South Med J 2000; 93(5): 479–87

    PubMed  CAS  Google Scholar 

Download references

Acknowledgement

Dr Davis has no conflicts of interest directly relevant to the content of this commentary.

Dr Sachs has no conflicts of interest directly relevant to the content of this commentary.

Dr McCarberg has no conflicts of interest directly relevant to the content of this commentary.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health | Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Philip I. Hair, Monique P. Curran & Susan J. Keam

Authors
  1. Philip I. Hair
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monique P. Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip I. Hair.

Additional information

Adapted and reproduced from Drugs 2006; 66 (15): 2017-30.[1–4] The manufacturer of the agent under review was offered an opportunity to comment on the original article[1] during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hair, P.I., Curran, M.P. & Keam, S.J. Tramadol Extended-Release Tablets in Moderate to Moderately Severe Chronic Pain in Adults. CNS Drugs 21, 259–263 (2007). https://doi.org/10.2165/00023210-200721030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200721030-00005

Keywords

Search

Navigation